I was disappointed to read that Merck PD1 would not be getting approved till 2015! 😥
In this article Merck is stating the following:
“Merck said Sunday it plans to start late-stage clinical trials testing lambrolizumab in patients with a deadly form of skin cancer, melanoma, as well as non-small-cell lung cancer, in the third quarter. If all goes well, the company could file for regulatory approval in 2015.”
Unfortuntely, Merck is under huge investor pressure. They spend $8 billion on R&D but newly appointed head of R&D Roger Pearlmutter has had his budget cut and along with federal sequester cuts, this 2015 FDA approval date is more of a reality than just a PR spin. It really sucks for all of us, but there is not much we can do about thiis other than investing in Merck & BMS stocks in order to keep them investing in future cures.
Viewing 3 posts - 1 through 3 (of 3 total)
The forum ‘Melanoma Diagnosis: Stage IV’ is closed to new topics and replies.